This includes the use of machine learning models to predict anti-VEGF treatment demand in patients with retinal diseases treated according to a T&E regimen [27], and visual outcomes and treatment needs in T&E [20] and PRN regimens [22, 28] in nAMD. This evidence concerns the gene VEGFA and Abnormal retinal morphology.